Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Work In Process (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Work In Process for 5 consecutive years, with $3.6 million as the latest value for Q3 2018.

  • Quarterly Work In Process rose 379.89% to $3.6 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Sep 2018, up 379.89% year-over-year, with the annual reading at $66000.0 for FY2017, 97.49% down from the prior year.
  • Work In Process for Q3 2018 was $3.6 million at Theravance Biopharma, up from $3.3 million in the prior quarter.
  • The five-year high for Work In Process was $3.6 million in Q3 2018, with the low at $66000.0 in Q4 2017.
  • Average Work In Process over 4 years is $1.9 million, with a median of $2.0 million recorded in 2018.
  • The sharpest move saw Work In Process crashed 97.49% in 2017, then soared 379.89% in 2018.
  • Over 4 years, Work In Process stood at $145000.0 in 2014, then soared by 1711.72% to $2.6 million in 2016, then plummeted by 97.49% to $66000.0 in 2017, then soared by 5396.97% to $3.6 million in 2018.
  • According to Business Quant data, Work In Process over the past three periods came in at $3.6 million, $3.3 million, and $2.0 million for Q3 2018, Q2 2018, and Q1 2018 respectively.